Sarcopenia, the progressive loss of skeletal muscle mass and strength with age, is one of the strongest predictors of falls, fractures, loss of independence, and metabolic decline in older adults. It is driven by impaired proteostasis: the balance between protein synthesis and breakdown shifts, pushed by chronic low-grade inflammation, hormonal change, and reduced nutrient absorption.
TUDCA is best known in bodybuilding circles as liver support during oral steroid cycles, which is a completely different use case from what this article covers. The question here is narrower and more interesting: does TUDCA act on skeletal muscle itself? A 2026 study in aging mice, plus one older human trial that happened to measure muscle, are the evidence base. Nothing here is medical advice.
Key Takeaways
- 18-month-old mice treated with TUDCA for 20 days showed decreased body weight alongside increased skeletal muscle mass, restored muscle fibre size, and preserved functional integrity, compared with vehicle [1].
- TUDCA enhanced skeletal muscle insulin sensitivity through increased AKT activation and reduced tissue inflammation in those mice [1].
- Markers of protein synthesis rose, including phosphorylation of P70S6K and 4EBP1, the key anabolic signalling nodes downstream of mTOR [1].
- The single relevant human trial gave TUDCA to obese men and women and found improved muscle and liver insulin sensitivity, but not adipose tissue [2]. It measured insulin sensitivity, not muscle mass or strength.
- No human trial has tested TUDCA for sarcopenia, muscle mass, or strength at any age.
Why a Bile Acid Would Act on Muscle at All
The connection is less strange than it first appears. Bile acids are signalling molecules, not just detergents: they act on the nuclear receptor FXR and the membrane receptor TGR5, both of which are expressed outside the gut and liver. TUDCA separately acts as a chemical chaperone reducing ER stress, and ER stress in aging skeletal muscle contributes to the impaired proteostasis that defines sarcopenia.
The 2026 study’s authors arrived at the muscle question by a specific route: their group had previously shown TUDCA improves cognition and metabolic homeostasis in aging and Alzheimer‘s disease mouse models, and in those studies TUDCA treatment was also associated with increased skeletal muscle mass. That incidental observation is what prompted them to test muscle directly [1].
The Aging Mouse Study
The design was straightforward: 18-month-old C57BL/6 mice (roughly equivalent to late middle age in humans) were treated with TUDCA or vehicle for 20 days, with 3-month-old mice serving as a young control group for reference [1].
TUDCA treatment decreased body weight while increasing skeletal muscle mass. That combination is notable: weight loss usually costs lean mass, so gaining muscle while losing weight suggests the loss was disproportionately fat. Muscle fibre size was restored and functional integrity preserved [1].
On mechanism, TUDCA enhanced skeletal muscle insulin sensitivity through increased AKT activation and reduced tissue inflammation. Markers of protein synthesis increased, including phosphorylation of ribosomal protein S6 kinase beta-1 (P70S6K) and eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) [1]. Those two are the standard readouts for mTOR-driven anabolic signalling, the same pathway that resistance training and protein intake activate.
The authors framed the collective result as restoration of skeletal muscle proteostasis, and TUDCA as a promising strategy against age-related muscle loss [1]. ‘Promising strategy’ is appropriately hedged language for a 20-day mouse study.
The Human Trial That Touched Muscle
There is one randomized human TUDCA trial relevant here, and it was not a muscle study. It gave TUDCA to obese men and women and measured tissue-specific insulin sensitivity, finding improvement in liver and muscle insulin sensitivity but not in adipose tissue [2].
That matters because muscle insulin sensitivity is mechanistically upstream of muscle nutrient uptake, and impaired insulin signalling in aging muscle (anabolic resistance) is part of why older adults need more protein per meal to trigger the same synthetic response. So the human trial confirms TUDCA can reach and act on human skeletal muscle in a measurable way.
It does not show that this translates into more muscle. The trial measured a metabolic parameter over a short period in obese adults, not muscle mass or strength in older adults. The bridge from ‘improves muscle insulin sensitivity’ to ‘preserves muscle with age’ has not been built in humans.
Related Bile Acid and Muscle Research
Work outside TUDCA specifically has begun connecting bile acid metabolism to muscle regeneration in aging, in a manner associated with regulation of ABCB1 expression [3]. This is early and mechanistic, but it suggests the TUDCA finding sits in a broader emerging picture rather than being an isolated result.
What This Evidence Can and Cannot Tell Us
What it can tell us: in aged mice, three weeks of TUDCA increased muscle mass, restored fibre size, improved muscle insulin signalling, reduced muscle inflammation, and raised anabolic signalling markers [1]. That is a coherent, multi-level result in an appropriate aging model, and it is more than most supplements marketed for muscle can claim.
What it cannot tell us: whether any of this happens in people. No human trial has measured muscle mass, strength, physical function, or sarcopenia progression with TUDCA at any dose. Mouse aging studies at 20 days are also short relative to a process that unfolds over human decades.
For anyone actually worried about age-related muscle loss, the interventions with human outcome evidence are unglamorous and well established: progressive resistance training and adequate protein intake distributed across meals. Those are not competing with TUDCA for attention, because TUDCA has no human sarcopenia evidence to compete with. Anyone on medication or with liver or gallbladder conditions should raise TUDCA with a clinician before adding it.
Frequently Asked Questions
Does TUDCA build muscle?
In aged mice, 20 days of TUDCA increased skeletal muscle mass and restored fibre size [1]. No human trial has measured muscle mass with TUDCA, so there is no basis to claim this in people.
Is this the same as TUDCA for steroid cycles?
No. That use is about protecting the liver from the cholestatic effects of oral 17-alpha-alkylated compounds and is covered separately on this site. The aging research is about TUDCA acting on muscle tissue itself, a different mechanism and a different question.
What dose was used in the mouse study?
The published summary describes 20 days of TUDCA treatment in 18-month-old C57BL/6 mice [1]. Mouse dosing does not convert directly to human dosing, and no human dose for muscle outcomes has been established because no human trial exists.
Should older adults take TUDCA for sarcopenia?
There is no human evidence supporting that. Resistance training and adequate protein intake have human outcome data behind them; TUDCA for muscle has a 20-day mouse study [1] and a human trial that measured insulin sensitivity rather than muscle [2].
References
- Tauroursodeoxycholic acid (TUDCA) ameliorates age-related skeletal muscle loss. The Journal of Physiology (2026).
- Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes (2010).
- Bile Acid Metabolism Affects Muscle Regeneration in Aging Skeletal Muscle in a Manner Associated with Regulation of ABCB1 Expression. International Journal of Molecular Sciences (2026).
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
